|
- label - accessdata. fda. gov
These highlights do not include all the information needed to use TRYNGOLZA safely and effectively See full prescribing information for TRYNGOLZA
- Tryngolza: Package Insert Prescribing Information MOA
Tryngolza package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
- Support Resources | TRYNGOLZA® (olezarsen) Injection
Access downloadable resources and watch videos to support your TRYNGOLZA® treatment journey See Safety Full Prescribing Information
- PATIENT INFORMATION TRYNGOLZA [trin-GOLE-zah] (olezarsen . . .
Do not use TRYNGOLZA if: • you have had a serious allergic reaction to olezarsen or any of the ingredients in TRYNGOLZA See the end of this Patient Information for a complete list of ingredients , tell your healthcare provider about all of your medic It is not known if TRYNGOLZA can harm your
- Tryngolza | European Medicines Agency (EMA)
Tryngolza can only be obtained with a prescription and is available as a solution for injection in prefilled pens It is injected once a month under the skin in the abdomen (belly), the front of the thigh or the back of the upper arm Patients or their carers can inject Tryngolza themselves once they have been trained For more information about using Tryngolza, see the package leaflet or
- UM PrimaryTemplate - info. caremark. com
Specialty Guideline Management Tryngolza Products Referenced by this Document Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated Over-the-counter (OTC) products are not included unless otherwise stated
- HIGHLIGHTS OF PRESCRIBING INFORMATION adverse reactions, and . . .
Risk Summary There is no information regarding the presence of tislelizumab-jsgr in human milk, or its effects on the breastfed child or on milk production Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose of TEVIMBRA
- First FDA-Approved Medicine for FCS | TRYNGOLZA®
TRYNGOLZA® (olezarsen) is an FDA-approved treatment in adults with FCS as an adjunct to diet See Safety Full Prescribing Information
|
|
|